



IFW

PATENT  
Attorney Docket No. 056291-5223

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Anderson Joseph RYAN**

Application No.: 10/561,183

Filed: **December 16, 2005**For: **COMPOSITIONS COMPRISING ZD6126  
TOGETHER WITH 5-FU, CPT-11 OR 5-FU AND  
CPT-11 HAVING VASCULAR DAMAGING  
ACTIVITY FOR TREATING E.G.  
COLORECTAL CANCER**Group Art Unit: *Unassigned*Examiner: *Unassigned*Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Window, **Mail Stop Amendment**  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314Dated: **April 12, 2006**

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)****Citation of Related U.S. Patent Applications**

The Examiner's attention is directed to the following related co-pending U.S. patent applications:

Inventor	U.S. Serial No. Filing Date	U.S. Patent No. Issue Date	PCT Publication No. PCT Publication Date
Stephen Robert WEDGE	10/563,440 05-Jan-2006		WO 2005/004871 January 20, 2005

A copy of the specification and claims for each application, in the form of the published PCT application from which such application was filed is being filed herewith.

**PLEASE DO NOT PRINT** the above information on the patent resulting from the subject application.

Consideration of each listed application is earnestly solicited since unpublished patent applications are contemplated as IDS material; see the exception in Rule 98(a)(2)(iii) and note the penultimate sentence of MPEP 609.

Further, in keeping with MPEP 609, Subsec. C(2), 2nd para., line 10 to end of the paragraph (especially note lines 18-25) PLEASE RETURN A COPY OF THIS LETTER with the Examiner's initials adjacent each above listing so that applicant will know that each listed application has been considered as required by PTO policy.

**Citation of Documents**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants petition the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

With the exception of U.S. Patents and published U.S. Applications, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that the listed documents constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


**Except** for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or

credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a

**CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R.

§1.136(a)(3).

Respectfully Submitted,  
**Morgan Lewis & Bockius LLP**



Date: April 12, 2006  
Morgan Lewis & Bockius LLP  
Customer No. 09629  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel. No.: 202-739-3000

By:

Donald J. Bird  
Registration No. 25,323  
Tel. No.: (202) 739-5320  
Fax No.: (202) 739-3001

(Use several sheets if necessary)

Application No.  
10/561,183

PTO Form 1449

**Group Art Unit: Unassigned**

	Document No.	Date	Name	Class	Sub-Class	Filing Date
1.	6906048	June 14, 2005	Davis et al.	514	119	March 27, 2001
2.	6846925	January 25, 2005	Arnould	544	154	November 12, 2003
3.	6720323	April 13, 2004	Arnould	514	237.5	January 7, 2003
4.	6423753	July 23, 2002	Dougherty	514	719	January 5, 2000
5.	20050277627	December 15, 2005	Arnould et al.	514	217	January 6, 2003
6.	20050215530	September 29, 2005	Ryan	514	114	October 18, 2004
7.	20030166617	September 4, 2003	Davis et al.	514	114	April 4, 2003
8.	20030144298	July 31, 2003	Curwen et al.	514	252.17	October 1, 2002
9.	20030055024	March 20, 2003	Davis	514	114	September 26, 2002

	Document No.	Date	Country	Class	Sub-Class	Translation
10.	WO 99/02166	January 21, 1999	WIPO			
11.	WO 00/40529	July 13, 2000	WIPO			
12.	WO 00/48591	August 24, 2000	WIPO			
13.	WO 01/74360	October 11, 2001	WIPO			
14.	WO 01/74368	October 11, 2001	WIPO			
15.	WO 01/74369	October 11, 2001	WIPO			
16.	WO 02/04434	January 17, 2002	WIPO			
17.	WO 02/08213	January 31, 2002	WIPO			
18.	WO 03/088971	October 30, 2003	WIPO			
19.	WO 04/032939	April 22, 2004	WIPO			
20.	WO 2005/004871	January 20, 2005	WIPO			
21.	WO 2005/061436	July 7, 2005	WIPO			
22.	WO 2005/110426	November 24, 2005	WIPO			

23.	Bleiberg H (1998 ) "Continuing the fight against advanced colorectal cancer: new and future treatment options" <i>Anticancer Drugs</i> 9(1):18-28
24.	Siemann DW et al. (2000) "Targeting tumor blood vessels: an adjuvant strategy for radiation therapy" <i>Radiother Oncol.</i> 57(1):5-12

Date Considered

1-WA/2547626.1